ReviewInternational journal of pharmaceutics: X2026
Emerging copper-based hollow nanoplatforms for cancer treatment.
Review in International journal of pharmaceutics: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanomedicines have significantly advanced tumor treatment, with hollow copper (Cu)-based nanostructures emerging as a uniquely promising nanoplatform. Their degradable frameworks enable controlled release of various therapeutic agents, facilitating chemotherapy, photothermal therapy (PTT), photodynamic therapy (PDT), immunotherapy, and related modalities. Simultaneously, liberated Cu ions drive chemodynamic therapy (CDT) via Fenton-like reactions and trigger cuproptosis. A critical effect of this combined action is the induction of immunogenic cell death (ICD), thereby amplifying antitumor immunity. Moreover, the inherent physicochemical properties of these nanostructures support multimodal diagnostic functions, which enable accurate imaging-guided interventions. Herein, we present a systematic overview of the latest developments in hollow Cu-based nanoplatforms, covering inorganic Cu nanostructures, Cu-doped composites, matrix-supported Cu systems, and Cu-based complexes, for diverse cancer therapies. We also discuss rational design strategies to achieve synergistic therapeutic outcomes and conclude with an analysis of translational challenges and future directions toward clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.